AYOXXA appoints permanent CEO
Cologne, December 7, 2016
The Supervisory Board of AYOXXA Biosystems GmbH is pleased to announce that following his initial assumption of the duties of CEO in October 2016, Rodney Turner will continue to lead the company as CEO on a permanent basis effective immediately. The board and Mr. Turner are aligned on the future growth opportunities for AYOXXA which focus on bringing it’s state-of-the-art LUNARIS™ multiplex immunoassay system to users for the first time, and expanding partnerships in the development and use of the platform.
Changes in the AYOXXA Management Team
The supervisory board of AYOXXA GmbH announces that Mr. Rodney Turner has assumed duties as the interim CEO of AYOXXA effective October 15, 2016. Mr. Turner is pleased to lead the company as its orientation shifts toward market development and product refinement. The supervisory board and the management team wish to thank Dr. Andreas Schmidt for his years of leadership in founding and establishing AYOXXA as a leading biotech start-up in Germany.
AYOXXA and Märzhäuser introduce a benchtop device for Protein Multiplex Analysis
AYOXXA Biosystems GmbH, an international biotechnology company, and Märzhäuser Wetzlar GmbH & Co KG, a leading precision equipment manufacturer, joined forces to develop a dedicated benchtop device for the analysis of LUNARIS™ Multiplex assays. The AYOXXA Reader AR01 expands the technology platform to offer researchers a complete, flexible and user-friendly system for multiprotein analysis. The device was approved for routine laboratory work use in biomedical research.
AYOXXA is Member of the International EYE-RISK Consortium
Cologne, October 22nd, 2015
AYOXXA Biosystems GmbH, an international biotechnology company, is one of two industrial partners of EYE-RISK, a large biomedical consortium bringing together the expertise of ten renown scientific and clinical institutions and a patient organization from six European countries. It is led by Prof. Dr. Marius Ueffing of the University Medical Center of Tübingen, Germany and Prof. Dr. Caroline Klaver of the Erasmus University Medical Center Rotterdam, Netherlands. AYOXXA contributes the LUNARIS™ technology platform to develop biomarker footprints to stratify patient subgroups.